Permanent Injunction Granted Against Foiled Amgen Patent Challengers
Citing irreparable harm and inadequacy of money damages, a Delaware federal judge on Thursday permanently enjoined Sanofi SA and Regeneron Pharmaceuticals from selling a product that infringed on the patents of a rival drugmaker.
This premium content is reserved for Delaware Law Weekly subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now